Claritas Pharmaceuticals, Inc.
CLAZF · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $0 | $1 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $1 | $0 | -$3 | -$3 |
| % Margin | – | – | – | – |
| Net Income | $0 | -$2 | -$2 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | 0.005 | -0.058 | -0.084 | -0.024 |
| % Growth | 108.8% | 30.4% | -246.9% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |